GLP-1 weight loss drugs work, but critical questions remain unanswered

Drugs like Ozempic and Mounjaro are generating tremendous excitement for weight loss, with new Cochrane reviews confirming they can produce clinically meaningful results. Tirzepatide led to about 16% weight loss over 12 to 18 months, semaglutide produced around 11% reduction, and liraglutide resulted in 4 to 5% weight loss.

These are substantial numbers that outperformed placebo consistently. However, here's what concerns me: most studies were funded and designed by the pharmaceutical companies manufacturing these drugs, raising questions about potential conflicts of interest. We have limited data on long-term safety beyond two years, uncertain evidence about cardiovascular outcomes in lower-risk individuals, and concerning patterns of muscle loss and weight regain after stopping treatment.

The reviews also found higher rates of gastrointestinal side effects, leading some participants to discontinue treatment. This study highlights these issues and invites caution as we continue to investigate these drugs.

In other words, people are trading weight loss with side effects. We need to be very carefully using those GLP1 peptides.

1 comment